FLT3 and acute myeloid leukemia: Several TKIs that achieve sustained in vivo inhibition of FLT3 have exhibited highly promising activity in early clinical studies10,34; however, none of them are able to ensure remission of AML as a single treatment9, primarily because of secondary resistance.